Jeff Evanson, Chief Commercial Officer at Outlook Therapeutics, Inc. (OTLK), sold 8,554 shares at $2.09 ($18K) on 2021-02-23, disclosed to the SEC on 2021-02-25.
Open-market sale of $18k OTLK by Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| OTLK | SELL | 2023-01-19 | $330K | — | Filing → |
| OTLK | BUY | 2021-12-06 | $47K | — | Filing → |
| OTLK | SELL | 2021-02-17 | $291K | — | Filing → |